Cargando…

AR Signaling in Human Malignancies: Prostate Cancer and Beyond

The notion that androgens and androgen receptor (AR) signaling are the hallmarks of prostate cancer oncogenesis and disease progression is generally well accepted. What is more poorly understood is the role of AR signaling in other human malignancies. This special issue of Cancers initially reviews...

Descripción completa

Detalles Bibliográficos
Autor principal:	Antonarakis, Emmanuel S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2018
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5789372/ https://www.ncbi.nlm.nih.gov/pubmed/29346310 http://dx.doi.org/10.3390/cancers10010022

Ejemplares similares

AR-Signaling in Human Malignancies: Prostate Cancer and Beyond
por: Schweizer, Michael T., et al.
Publicado: (2017)

Selective inhibitors of nuclear export: potential therapeutics for AR variant-expressing prostate cancer
por: Antonarakis, Emmanuel S.
Publicado: (2018)

AR Splicing Variants and Resistance to AR Targeting Agents
por: Kanayama, Mayuko, et al.
Publicado: (2021)

Germline genetic testing in prostate cancer – further enrichment in variant histologies?
por: Markowski, Mark C., et al.
Publicado: (2018)

Rucaparib for metastatic castration-resistant prostate cancer: did TRITON3 deliver a trifecta?
por: Elias, Roy, et al.
Publicado: (2023)

Crosstalk between KIF15 and AR in castrate-resistant prostate cancers
por: Yang, Hanny, et al.
Publicado: (2022)

Metastatic Castration-Resistant Prostate Cancer, Immune Checkpoint Inhibitors, and Beyond
por: Lanka, Sree M., et al.
Publicado: (2023)

Non-nuclear AR Signaling in Prostate Cancer
por: Zamagni, Alice, et al.
Publicado: (2019)

Clinical Implications of Hedgehog Pathway Signaling in Prostate Cancer
por: Suzman, Daniel L., et al.
Publicado: (2015)

Destroying the androgen receptor (AR)-potential strategy to treat advanced prostate cancer
por: Narayanan, Ramesh, et al.
Publicado: (2017)

AR-V7 in Metastatic Prostate Cancer: A Strategy beyond Redemption
por: Sobhani, Navid, et al.
Publicado: (2021)

Lysine Acetyltransferases and Their Role in AR Signaling and Prostate Cancer
por: Jaiswal, Bharti, et al.
Publicado: (2022)

Stilbene Induced Inhibition of Androgen Receptor Dimerization: Implications for AR and ARΔLBD-Signalling in Human Prostate Cancer Cells
por: Streicher, Wolfgang, et al.
Publicado: (2014)

AR Signaling and the PI3K Pathway in Prostate Cancer
por: Crumbaker, Megan, et al.
Publicado: (2017)

ACK1–AR and AR–HOXB13 signaling axes: epigenetic regulation of lethal prostate cancers
por: Kim, Eric H, et al.
Publicado: (2020)

Prostate Cancer: From Genomics to the Whole Body and Beyond
por: Grizzi, Fabio, et al.
Publicado: (2017)

Therapeutic targeting of the androgen receptor (AR) and AR variants in prostate cancer
por: Narayanan, Ramesh
Publicado: (2020)

Role of androgen receptor splice variant 7 (AR-V7) in prostate cancer resistance to 2(nd) generation androgen receptor signaling inhibitors
por: Zhu, Yezi, et al.
Publicado: (2020)

Stromal TGF-β signaling induces AR activation in prostate cancer
por: Yang, Feng, et al.
Publicado: (2014)

AR, the cell cycle, and prostate cancer
por: Balk, Steven P., et al.
Publicado: (2008)

Darolutamide For Castration-Resistant Prostate Cancer
por: Bastos, Diogo A, et al.
Publicado: (2019)

Undesirable Status of Prostate Cancer Cells after Intensive Inhibition of AR Signaling: Post-AR Era of CRPC Treatment
por: Makino, Tomoyuki, et al.
Publicado: (2021)

Increased AR expression in castration-resistant prostate cancer rapidly induces AR signaling reprogramming with the collaboration of EZH2
por: Labaf, Maryam, et al.
Publicado: (2022)

Clinical Evaluation of Abiraterone in the Treatment of Metastatic Prostate Cancer
por: Goyal, Jatinder, et al.
Publicado: (2013)

PARP Inhibitors in Metastatic Prostate Cancer: Evidence to Date
por: Nizialek, Emily, et al.
Publicado: (2020)

Co-expression and clinical utility of AR-FL and AR splice variants AR-V3, AR-V7 and AR-V9 in prostate cancer
por: Wüstmann, Neele, et al.
Publicado: (2023)

A New Molecular Taxonomy to Predict Immune Checkpoint Inhibitor Sensitivity in Prostate Cancer
por: Antonarakis, Emmanuel S.
Publicado: (2019)

Chemotherapy and its evolving role in the management of advanced prostate cancer
por: Schweizer, Michael T, et al.
Publicado: (2014)

PAQR6 Upregulation Is Associated with AR Signaling and Unfavorite Prognosis in Prostate Cancers
por: Yang, Min, et al.
Publicado: (2021)

Immunotherapy for Prostate Cancer Enters Its Golden Age
por: Boikos, Sosipatros A., et al.
Publicado: (2012)

Galeterone for the treatment of advanced prostate cancer: the evidence to date
por: Bastos, Diogo A, et al.
Publicado: (2016)

Resistance to Novel Antiandrogen Therapies in Metastatic Castration-Resistant Prostate Cancer
por: Boudadi, Karim, et al.
Publicado: (2016)

AR Signaling in Breast Cancer
por: Rahim, Bilal, et al.
Publicado: (2017)

Robotic surgery beyond the prostate
por: Aron, Monish
Publicado: (2014)

GABARAPL1 Promotes AR+ Prostate Cancer Growth by Increasing FL-AR/AR-V Transcription Activity and Nuclear Translocation
por: Su, Bing, et al.
Publicado: (2019)

Enzalutamide: an evidence-based review of its use in the treatment of prostate cancer
por: Golshayan, Ali R, et al.
Publicado: (2013)

Clinical utility of the nuclear-localized AR-V7 biomarker for treatment choice in metastatic castration-resistant prostate cancer
por: Vlaeminck-Guillem, Virginie
Publicado: (2020)

PLCɛ maintains the functionality of AR signaling in prostate cancer via an autophagy-dependent mechanism
por: Quan, Zhen, et al.
Publicado: (2020)

Crosstalk Between AR and Wnt Signaling Promotes Castration-Resistant Prostate Cancer Growth
por: Luo, Jun, et al.
Publicado: (2020)

Molecular Phenotyping of AR Signaling for Predicting Targeted Therapy in Castration Resistant Prostate Cancer
por: Hamid, Agus Rizal A. H., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_qj3o098u9o6f2j6om2bad53fbn